X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (37) 37
humans (27) 27
life sciences (25) 25
hematology (24) 24
female (19) 19
middle aged (18) 18
male (17) 17
cancer (15) 15
oncology (15) 15
survival (15) 15
aged (14) 14
multiple myeloma (13) 13
abridged index medicus (12) 12
adult (12) 12
dexamethasone (11) 11
bortezomib (10) 10
patients (9) 9
[sdv.can]life sciences [q-bio]/cancer (8) 8
lenalidomide (8) 8
prognosis (8) 8
retrospective studies (8) 8
survival rate (8) 8
history (7) 7
risk factors (7) 7
transplantation (7) 7
aged, 80 and over (6) 6
disease-free survival (6) 6
follow-up studies (6) 6
stem cell transplantation (6) 6
survival analysis (6) 6
[ sdv.can ] life sciences [q-bio]/cancer (5) 5
analysis (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
apoptosis (5) 5
historia (5) 5
lymphoma (5) 5
lymphomas (5) 5
remission (5) 5
autografts (4) 4
chemotherapy (4) 4
clinical trials (4) 4
criteria (4) 4
hemic and lymphatic diseases (4) 4
human health and pathology (4) 4
medical research (4) 4
multiple myeloma - drug therapy (4) 4
neutropenia (4) 4
recurrence (4) 4
rituximab (4) 4
stem-cell transplantation (4) 4
therapy (4) 4
treatment outcome (4) 4
[ sdv ] life sciences [q-bio] (3) 3
[sdv.mhep.hem]life sciences [q-bio]/human health and pathology/hematology (3) 3
[sdv]life sciences [q-bio] (3) 3
adolescent (3) 3
allografts (3) 3
article (3) 3
breast cancer (3) 3
breast neoplasms - pathology (3) 3
criticism and interpretation (3) 3
daratumumab (3) 3
diagnosis (3) 3
drug therapy (3) 3
expression (3) 3
france (3) 3
gene expression (3) 3
hodgkin disease - mortality (3) 3
hodgkin lymphoma (3) 3
impact (3) 3
induction chemotherapy (3) 3
leukemia (3) 3
leukemia, myeloid, acute - mortality (3) 3
medical prognosis (3) 3
medicine, experimental (3) 3
minimal residual disease (3) 3
multiple myeloma - pathology (3) 3
multiple myeloma - therapy (3) 3
multivariate analysis (3) 3
plus dexamethasone (3) 3
remission induction (3) 3
risk (3) 3
social conditions (3) 3
stem cells (3) 3
toxicity (3) 3
transplants & implants (3) 3
102 (2) 2
allogeneic transplantation (2) 2
angiogenesis (2) 2
antibodies, monoclonal, murine-derived - therapeutic use (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
apoptosis - drug effects (2) 2
b-cell lymphoma (2) 2
b-cells (2) 2
biology (2) 2
biomarkers (2) 2
biomarkers, tumor - blood (2) 2
biopsy (2) 2
blotting, western (2) 2
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (13) 13
UTL at Downsview - May be requested (4) 4
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Online Resources - Online (1) 1
Robarts - Storage (1) 1
Royal Ontario Museum - Rare Book (1) 1
Royal Ontario Museum - Stacks (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
UTL at Downsview - May be requested in 6-10 wks (1) 1
UofT at Scarborough - Stacks (1) 1
Victoria University E.J. Pratt - Rare Book (1) 1
Victoria University E.J. Pratt - Stacks (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Revue Projet, ISSN 0033-0884, 2016, Volume 350, Issue 1, pp. 95b - 96
Journal Article
Revue Francophone des Laboratoires, ISSN 1773-035X, 04/2019, Volume 2019, Issue 511, pp. 41 - 49
Les dyscrasies plasmocytaires, autres que le myélome multiple, ont des présentations cliniques extrêmement variées. Il peut s’agir de maladies indolentes liées... 
plasmocytome | amylose | amyloidosis | plasmocytoma | leucémie à plasmocytes | plasma cell leukemia
Journal Article
Revue Francophone des Laboratoires, ISSN 1773-035X, 04/2019, Volume 2019, Issue 511, p. 41
Journal Article
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 05/2018, Volume 38, Issue 38, pp. 675 - 680
In the past 15 years, significant improvements in overall survival have been observed in multiple myeloma (MM), mainly due to the availability of novel drugs... 
Multiple Myeloma - therapy | Genomics - methods | Humans | Risk Factors | Multiple Myeloma - genetics
Journal Article
The Lancet, ISSN 0140-6736, 07/2019, Volume 394, Issue 10192, pp. 29 - 38
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2019, Volume 187, Issue 3, pp. 319 - 327
Summary Single agent daratumumab has shown clinical activity in relapsed, refractory multiple myeloma (RRMM). The Intergroupe Francophone du Myélome 2014‐04... 
clinical trial | myeloma therapy | daratumumab | Dexamethasone | Multiple myeloma | Refractory materials | Infusion | Toxicity | Medical services | Toxic diseases | Survival | Patients
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2019, Volume 381, Issue 8, pp. 727 - 738
Journal Article
British Journal of Haematology, ISSN 0007-1048, 12/2018, Volume 183, Issue 5, pp. 755 - 765
Journal Article
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2017, Volume 179, Issue 3, pp. 439 - 448
Summary Histological transformation (HT) to diffuse large B‐cell lymphoma (DLBCL) is a rare and poorly reported complication of Waldenström macroglobulinaemia... 
chemoimmunotherapy | extranodal involvement | diffuse large B‐cell lymphoma | Waldenström macroglobulinaemia | histological transformation | diffuse large B-cell lymphoma | LYMPHOPLASMACYTIC LYMPHOMA | IMMUNOBLASTIC SARCOMA | CHEMOTHERAPY | TRANSPLANTATION | Waldenstrom macroglobulinaemia | B-CELL LYMPHOMA | INTERNATIONAL WORKSHOP | MUTATIONS | HEMATOLOGY | CHLORAMBUCIL | MYD88 | Doxorubicin - therapeutic use | Prognosis | Humans | Middle Aged | Male | Tomography, X-Ray Computed | Cyclophosphamide - therapeutic use | Waldenstrom Macroglobulinemia - pathology | Lymphoma, Large B-Cell, Diffuse - diagnostic imaging | Aged, 80 and over | Waldenstrom Macroglobulinemia - diagnostic imaging | Adult | Female | Retrospective Studies | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - pathology | Risk Factors | Treatment Outcome | Positron-Emission Tomography - methods | Biomarkers, Tumor - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Biopsy | L-Lactate Dehydrogenase - blood | Survival Analysis | Vincristine - therapeutic use | Fluorodeoxyglucose F18 | Aged | Cell Transformation, Neoplastic - pathology | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | PET imaging | Leukemia | Leptin | Oncology, Experimental | Lymphomas | Research | Health aspects | Cancer | Transformation | Emission analysis | Medical services | Central nervous system | Positron emission | Rituximab | Prednisone | Lymphoma | Patients | Doxorubicin | Vincristine | Cyclophosphamide | Lymphocytes B | Positron emission tomography | B-cell lymphoma | Index Medicus | Life Sciences | Hematology | Human health and pathology
Journal Article